-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/renal-function_disposition-comments.pdf
August 11, 2014 - state in the Discussion
chapter, Key Findings section for KQ2,
“Furthermore, many RCTs that tested
therapeutic … in patients with chronic
kidney disease help to determine the relative effectiveness of
specific therapies … The most disappointing
part of the conclusions (no fault of the systematic review) is the lack
of therapeutics … Should pharmacologists be a
target despite the fact that there are no therapeutic trials that reduce … The point that measurement of these biomarkers does is not yet
linked to additional specific therapies
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/plasma-cell-dyscrasias-sflc-assay-future_research.pdf
September 01, 2012 - o Does the use of the SFLC assay influence the type of treatment (e.g., radiation
therapy)? … of treatment or use of
adjunctive therapy or stem-cell transplantation) in patients with PCDs? … o Does the use of the SFLC assay influence the type of treatment (e.g., radiation
therapy)? … of treatment or
use of adjunctive therapy or stem-cell transplantation) in patients with PCDs? … Does the use of the SFLC assay influence the type of treatment (e.g.,
radiation therapy)?”
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/transparency-tympanostomy_research-protocol.pdf
September 02, 2016 - registries and publications.8-
11
Despite efforts to spur pediatric research, children remain “therapeutic … Therapeutic orphans. Pediatrics. 1999 Sep;104(3 Pt 2):583-4. PMID:
10469793.
13. … Clinical therapeutics. 2014 Feb 1;36(2):156-62. PMID:
24529287.
15. … effectiveness of tympanostomy tubes, compared to watchful
waiting with episodic or prophylactic antibiotic therapy … Pathogens cultured from otorrhea
• KQ 5 Treatment of otorrhea:
o Final health or patient-centered
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/colorectal-cancer-liver-metastases-therapies_disposition-comments.pdf
December 11, 2012 - Many of these studies
show survival benefit and therapeutic effectiveness. … to one another, but it is
outside the scope of the report for the authors to
comment on if these treatments … did these patients
receive their treatment? … In my opinion, there should be more detail in the Tables with regards to
previous treatments (i.e., … Since
these treatments are available to them off trial, patients do not want to
enroll in studies and
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/bariatric-surgery_research.pdf
June 01, 2010 - Lipid-lowering therapies decreased by 55% and 52% among enrollees with and without diabetes,
respectively … Adjustable gastric banding and conventional
therapy for type 2 diabetes: a randomized
controlled … An operation
proves to be the most effective therapy for adult-
onset diabetes mellitus. … Medications HMG-CoA reductase inhibitor
fibrates
niacin
bile acid sequestrant
other lipid lowering therapies … Diabetes Treatments insulin
pramlintide
sulfonylureas
biguanides
thiazolidinedione
alpha
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/distributed-network-ambulatory-therapeutics_research.pdf
July 01, 2009 - , and assess long-term outcomes of treatments. … and assess long-term outcomes of
treatments. … will be data elements that are essential to
understanding the effectiveness or safety related to therapeutic … Persistence with initial ODM therapies differed across specific monotherapy and
combination therapy … Glycemic response to newly initiated
diabetes therapies.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/medication-therapy-management_research-protocol.pdf
January 01, 2014 - developed a consensus definition of MTM as “a distinct service or group
of services that optimize therapeutic … the CMR as “a systematic process of collecting patient-specific information,
assessing medication therapies … designed to improve patients’ knowledge of their
prescriptions, over-the-counter medications, herbal therapies … substitution issue; complex regimen that can
be simplified with same therapeutic benefit; and potential … We will also consider
conducting mixed-treatment comparisons in a meta-analysis using Bayesian methods
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/atypical-antipsychotics-seniors-death_research.pdf
August 01, 2007 - Results: 12,882 seniors initiated conventional APM therapy and 24,359 atypical APMs. … Clin Therapeutics 2002; 24(9): 1466-
76.
6 Health Canada. … J Am Stat Assoc 1983; 79: 516-524.
26 Braitman LE, Rosenbaum PR: Rare outcomes,
common treatments … A review of uses of health
care utilization databases for epidemiologic
research on therapeutics. … 1.60 (1.42-1.80)
40-79 Days after beginning therapy 1.31 (1.14-1.51)
80-180 Days after beginning therapy
-
effectivehealthcare.ahrq.gov/sites/default/files/han.pdf
December 26, 2012 - and representations of different sources of uncertainty
in the example of outcomes of breast cancer treatment … • Probability: 20% probability of benefit from treatment (Indeterminacy of
future
outcome)
• … Ambiguity:
o 10-‐30%
probability of benefit from treatment (Imprecision)
o Expert disagreement … about benefits of treatment
o (Conflicting opinion/evidence)
o Insufficient
scientific evidence … )
to predict
a diagnostic or therapeutic outcome
-
effectivehealthcare.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1506.pdf
June 01, 2015 - , screening and diagnostics, therapeutics, surgery, programs, and
care delivery innovations that address … with one or more standard therapies, including
corticosteroids, immunomodulators, or tumor necrosis … unmet
need for new therapeutic options for patients with IBS. … , alternative therapies are needed. … FDA approves two therapies to treat IBS-D.
[internet]. Silver Spring (MD): U.S.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ahrq-healthcare-horizon-scan-protocol-operations-manual-151001.pdf
September 01, 2015 - , screening and diagnostics, therapeutics, surgery, and care delivery
innovations—which are referred … Potential to change current treatment models
ii. … The
MarketScan Treatment Pathways data analytics tool was used to estimate costs of existing
treatments … , and clinical,
therapeutic, industry and socioeconomic
issues
X X X X X
Cardiovascular Update … treatments.
-
effectivehealthcare.ahrq.gov/sites/default/files/ahrq-healthcare-horizon-scan-protocol-operations-manual-151001.pdf
September 01, 2015 - , screening and diagnostics, therapeutics, surgery, and care delivery
innovations—which are referred … Potential to change current treatment models
ii. … The
MarketScan Treatment Pathways data analytics tool was used to estimate costs of existing
treatments … , and clinical,
therapeutic, industry and socioeconomic
issues
X X X X X
Cardiovascular Update … treatments.
-
effectivehealthcare.ahrq.gov/sites/default/files/10_obesity_potential_high_impact_june_2012.pdf
January 01, 2012 - new (and new uses of existing) pharmaceuticals, medical devices,
diagnostic tests and procedures, therapeutic … , screening and diagnostics, therapeutics, surgery, programs, and care delivery
innovations that address … (Contrave
®
, Orexigen Therapeutics, Inc., La Jolla, CA in
collaboration with Takeda Pharmaceutical … New drug treatment options are needed for
obese patients seeking medical therapy for weight loss. … Goods Administration for inclusion in its therapeutic goods registry for treating T2DM
and obesity
-
effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1506.pdf
June 01, 2015 - therapeutic effects and better glycemic control. … therapeutic effects and better glycemic control. … Both anti-
angiogenic and corticosteroid treatments require ongoing treatment involving multiple intravitreal … Hayward (CA): Intarcia Therapeutics, Inc.;
2009. 1 p. … Investigational
therapeutic options in the management of DME:
investigational pharmacologic treatments
-
effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1506.pdf
June 01, 2015 - , screening and diagnostics, therapeutics, surgery, programs, and
care delivery innovations that address … for patients whose conditions fail to
respond to available medications and behavioral therapies for … Personalized drug therapy has traditionally lagged behind behavioral
therapy in this regard because … Double-blind,
placebo-controlled trial of ketamine therapy in
treatment-resistant depression (TRD … Therapeutic options in
treatment-resistant depression. Ann Med.
2011 Nov;43(7):512-30.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetic-neuropathy_research-protocol.pdf
May 09, 2016 - Table A: Inclusion/Exclusion Criteria
KQ1a(Pharmacologic treatments) KQ2a(Pharmacologic treatments) … KQ1b(Non-pharmacologic treatments) KQ2b(Non-pharmacologic
For prevention of DPN Complications treatments … [tiab] OR therapies[tiab]) AND (moving[tiab] OR
sports[tiab])))
OR “Stair Navigation”[tiab] OR postural … therapy”[tiab] OR “cognitive Psychotherapy”[tiab]
OR “behavioral therapy”[tiab] OR “behavioral therapies … Xylocaine (Lidocaine) AstraZeneca
Qutenza (Capsaicin) Acorda Therapeutics, Inc
20
!
-
effectivehealthcare.ahrq.gov/products/calcineurin-inhibitor/research
-
effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1406.pdf
June 01, 2014 - , screening and diagnostics, therapeutics, surgery, programs, and
care delivery innovations that address … cognitive behavior therapies. … efficacy for suicidal ideation
and as an adjunct treatment to behavior and brain-stimulation therapies … added to existing therapies. … Therapeutic options in
treatment-resistant depression. Ann Med. 2011
Nov;43(7):512-30.
-
effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1306.pdf
January 01, 2016 - Many
patients with T2DM do not meet treatment goals and require additional therapy with one of two … Some patients with T2DM also
need insulin therapy, but most undergo treatment with pharmacotherapy … Other treatment options, such as anti-VEGF therapies are available for treating DME, and
according … (e.g., anti-VEGF therapies). … Intarcia Therapeutics. A study to evaluate ITCA
650 for the treatment of type 2 diabetes.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/autism-medical-update_research-protocol.pdf
February 16, 2016 - b) Is the effectiveness of the therapies reviewed affected by co-interventions or prior
treatment … targeting sensory challenges as driving outcomes, either
within a single treatment or across treatments … [sh] OR therapeutics[mh] OR teaching[mh] OR psychotherapy[mh] OR
treatment outcome[mh]
7275093 …
5 (treatment[tiab] OR therapy[tiab] OR intervention[tiab] OR “control group”[tiab]
OR … "[Mesh]) OR ( "drug therapy" [Subheading] OR "Medication
Therapy Management"[Mesh] )
2368930